Interferon (IFN) inhibitors are a class of chemical compounds designed to specifically target and inhibit the biological activity of interferons, a group of signaling proteins that play a central role in regulating immune responses and cellular communication. Interferons are classified into three major types-Type I, II, and III-each with distinct receptors and signaling pathways, but all contributing to the modulation of gene expression in response to stimuli such as viral infections, cellular stress, or immune signaling. IFNs act by binding to their specific receptors on the cell surface, triggering intracellular signaling cascades that lead to the activation of transcription factors and the expression of various genes involved in immune regulation, inflammation, and cell proliferation. Interferon inhibitors are designed to block these interactions, preventing the downstream signaling and cellular responses that are typically induced by interferons.
The design of IFN inhibitors generally focuses on targeting either the interferon proteins themselves or their specific receptors. These inhibitors may function by directly binding to interferon molecules, preventing them from interacting with their cell surface receptors, or by blocking the receptors to impede the binding of interferons. The interaction between IFN inhibitors and their targets involves various non-covalent forces such as hydrogen bonding, van der Waals forces, and hydrophobic interactions, ensuring specificity and strong binding. Through the use of IFN inhibitors, researchers can dissect the complex roles that interferons play in regulating immune responses, inflammation, and cellular communication. These inhibitors provide valuable insights into the molecular mechanisms underlying interferon signaling, offering a deeper understanding of how this class of cytokines influences cellular functions, including gene expression, immune activation, and intercellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that has been used to target the JAK-STAT pathway, which is involved in interferon signaling. While its primary use has been in myelofibrosis and polycythemia vera, it may have implications for interferon-related conditions. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is another JAK inhibitor that has been investigated for its effects on interferon signaling and immune modulation. It is studied in the research of rheumatoid arthritis and may have broader applications. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib is a JAK1 inhibitor that may impact interferon signaling pathways, with applications in rheumatoid arthritis and other inflammatory conditions. | ||||||